How Cholinergic Interneurons Affect Nicotine Withdrawal
Author Information
Author(s): Kim Baeksun, Kim Han Ah, Woo Junsung, Lee Hyeon‐Jeong, Kim Tae Kyoo, Min Hophil, Lee C. Justin, Im Heh‐In
Primary Institution: Korea Institute of Science and Technology
Hypothesis
Striatal cholinergic interneurons play a critical role in the physical symptoms of nicotine withdrawal.
Conclusion
Inhibiting striatal cholinergic interneurons or using the drug procyclidine can reduce the physical signs of nicotine withdrawal.
Supporting Evidence
- The inhibition of striatal cholinergic interneurons significantly reduced the somatic signs of nicotine withdrawal.
- Procyclidine treatment mimicked the effects of striatal ChI inhibition on physical withdrawal signs.
- Cholinergic interneurons are critical for the regulation of dopamine release during nicotine withdrawal.
- Genetic inhibition of striatal ChIs did not affect other nicotine-dependent behaviors.
Takeaway
When mice had their brain cells that help control movement turned off, they showed fewer signs of feeling sick from not having nicotine, which suggests these cells are important for how we feel when we stop smoking.
Methodology
The study used genetic inhibition of striatal cholinergic interneurons in mice and assessed their behavior and neural activity during nicotine withdrawal.
Potential Biases
Potential bias due to the specific mouse model used and the lack of gender consideration.
Limitations
The study did not consider gender effects and used a specific mouse line that may not fully represent nicotine physiology.
Participant Demographics
Mice were used in the study, with no specific demographic details provided.
Statistical Information
P-Value
0.0021
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website